The nuclear factor-kappa B pathway and response to treatment in breast cancer

被引:30
|
作者
Park, Yeon Hee [1 ,2 ,3 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Dept Med, Seoul 06351, South Korea
[2] Sungkyunkwan Univ, Sch Med, Biomed Res Inst, Samsung Med Ctr, Seoul 06351, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Adv Inst Hlth Sci & Technol, Seoul 06351, South Korea
关键词
breast cancer; NF-kappa B; RANKL; EPITHELIAL-MESENCHYMAL TRANSITION; TYROSINE KINASE INHIBITOR; INDUCIBLE CHEMORESISTANCE; CHEMOTHERAPY RESISTANCE; INCREASED APOPTOSIS; THERAPEUTIC TARGET; COLORECTAL-CANCER; XENOGRAFT MODEL; GENE-EXPRESSION; CELLS;
D O I
10.2217/pgs-2017-0044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The nuclear factor-kappa B (NF-kappa B) pathway is known to contribute to critical signaling in cancer biology, including breast cancer, through promotion of proliferation, angiogenesis, metastasis, tumor progression, inflammation and cell survival. In this review, in vivo and in vitro studies of the NF-kappa B pathway in breast cancer are discussed, focusing on DNA damage and the epithelial-mesenchymal transition associated with breast cancer stem cell properties. The relationships between NF-kappa B signaling and conventional cancer treatments in terms of response to chemo-and radiotherapy will also be discussed. Then contribution and involvement of immune system in the NF-kappa B pathway will be covered. Furthermore, the future perspective of NF-kappa B targeting as an innovative strategy to overcome refractory breast cancer, including recent updates on out-receptor activator of NF-kappa B (RANKing), will be covered.
引用
收藏
页码:1697 / 1709
页数:13
相关论文
共 50 条
  • [1] The transcription factor nuclear factor-kappa B and cancer
    Escarcega, R. O.
    Fuentes-Alexandro, S.
    Garcia-Carrasco, M.
    Gatica, A.
    Zamora, A.
    CLINICAL ONCOLOGY, 2007, 19 (02) : 154 - 161
  • [2] Targeting the nuclear factor-kappa B pathway in stroke
    不详
    FUTURE NEUROLOGY, 2006, 1 (01) : 9 - 9
  • [3] MAFIP is a tumor suppressor in cervical cancer that inhibits activation of the nuclear factor-kappa B pathway
    Li, Yang
    Yu, Yao
    Zhang, Yan
    Zhou, Yufei
    Li, Chao
    Zhu, Jianbing
    Yuan, Hanying
    Lu, Hong
    CANCER SCIENCE, 2011, 102 (11) : 2043 - 2050
  • [4] Nuclear factor-kappa beta pathway and endometrial cancer: a pilot study
    Yilmaz, E.
    Coskun, E. I.
    Gul, M.
    Sahin, N.
    Tuncay, G.
    Simsek, Y.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2017, 38 (04) : 536 - 540
  • [5] Nuclear factor-kappa B pathways in Drosophila
    S Minakhina
    R Steward
    Oncogene, 2006, 25 : 6749 - 6757
  • [6] Nuclear factor-kappa B activity and arterial response to balloon injury
    Cercek, B
    Yamashita, M
    Dimayuga, P
    Zhu, J
    Fishbein, MC
    Kaul, S
    Shah, PK
    Nilsson, J
    Regnstrom, J
    ATHEROSCLEROSIS, 1997, 131 (01) : 59 - 66
  • [7] Response to "Which side is nuclear factor-kappa B on in liver injury?"
    Yoshidome, Hiroyuki
    Iida, Ayako
    Kimura, Fumio
    Shimizu, Hiroaka
    Ohtsuka, Masayuki
    Miyazaki, Masaru
    SURGERY, 2011, 149 (03) : 460 - 461
  • [8] Nuclear factor-kappa B activity in medulloblastoma
    Spiller, S. E.
    Logsdon, N. J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 356 - 356
  • [9] The Role of the Transcription Factor Nuclear Factor-kappa B in Thyroid Autoimmunity and Cancer
    Giuliani, Cesidio
    Bucci, Ines
    Napolitano, Giorgio
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [10] Role of nuclear factor-kappa B in atherogenesis
    Brand, K
    Page, S
    Walli, AK
    Neumeier, D
    Baeuerle, PA
    EXPERIMENTAL PHYSIOLOGY, 1997, 82 (02) : 297 - 304